[A25-55] Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2025
Project no.:
A25-55
Commission:
Commission awarded on 29.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Routine prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors and of 12 years of age or more
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-55
| Project no. | Title | Status |
|---|---|---|
| A25-56 | Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V | Commission completed |